Nature has tiny molecular machines — enzymes — that can add oxygen to molecules with surgical precision. Chemical factories do the same thing, but with toxic reagents, high temperatures, and lots of waste. OXYTRAIN trained a new generation of scientists to understand and engineer these oxygen-adding enzymes so industries like textiles, pharmaceuticals, and biorefineries can swap out dirty chemistry for clean biology. Think of it as replacing a blowtorch with a laser pointer — same job, far less collateral damage.
Many industries — textiles, pharmaceuticals, biorefineries — rely on harsh chemical oxidation processes that generate toxic waste, require extreme conditions, and deliver poor selectivity. Conventional oxygenation methods are expensive, environmentally damaging, and often cannot produce the precise molecular structures that modern products demand. Companies need cleaner, more precise alternatives that work under mild conditions and reduce both cost and environmental liability.
The project generated concrete enzyme tools: 6 SSB mutant libraries transferred to screening partners (RWTH/TUG), and LPMO mutant libraries checked for activity. Across 27 total deliverables, the consortium produced characterized oxygenase variants, training materials, and cross-sector knowledge exchange between 7 academic and 8 industrial partners.
If you are a textile manufacturer dealing with toxic oxidation steps in dye production — this project developed enzyme mutant libraries and biocatalytic methods that can replace conventional chemical oxidants. With 8 industrial partners already validating enzyme applications, these tools could cut your hazardous waste streams and reduce regulatory compliance costs for chemical handling.
If you are a pharmaceutical company struggling with expensive and low-yield oxygenation reactions in drug synthesis — OXYTRAIN produced engineered oxygenase variants across 27 deliverables that perform selective oxygen insertion under mild conditions. This means fewer synthetic steps, higher purity, and the potential to access chemical structures that are difficult to make with traditional catalysts.
If you are a biorefinery looking to upgrade low-value biomass streams into higher-value oxygenated chemicals — OXYTRAIN's consortium of 15 partners across 7 countries developed LPMO (lytic polysaccharide monooxygenase) mutant libraries specifically designed to break down and modify plant-based materials. These enzymes work at room temperature and atmospheric pressure, cutting your energy costs.
OXYTRAIN was a Marie Skłodowska-Curie training network, so its primary output is trained researchers and published knowledge rather than a single licensable product. Licensing would need to be negotiated directly with the coordinator (Rijksuniversiteit Groningen) or the specific industrial partners who co-developed particular enzyme variants. Costs would depend on the application scope and exclusivity terms.
The project focused on generating and characterizing enzyme mutant libraries — including 6 SSB mutant libraries and LPMO mutant libraries — which are research-stage tools. Scaling to industrial volumes would require further enzyme optimization, fermentation scale-up, and process engineering. The 8 industrial partners in the consortium may have advanced some variants closer to production readiness.
IP from MSCA training networks is typically shared between the host institution and the researcher, governed by the grant agreement and institutional policies. With 15 partners across 7 countries, IP is likely distributed across multiple institutions. A freedom-to-operate assessment would be needed before commercializing any specific enzyme variant.
Based on the deliverables, the project produced SSB (site-saturation by benchmarking) mutant libraries and LPMO (lytic polysaccharide monooxygenase) mutant libraries. These cover enzymes for selective oxygenation reactions relevant to textiles, pharmaceuticals, and biorefineries as stated in the project objectives.
The project ran from 2017 to 2021 and produced foundational enzyme libraries and trained researchers. Based on the deliverable descriptions — focused on generating and screening mutant libraries — the technology is at an early research stage. Deployment in production would likely require 3-5 more years of application-specific development and optimization.
Industrial enzymes are regulated differently depending on the application. For textile use, regulatory barriers are relatively low. For pharmaceutical synthesis, enzyme-produced intermediates must meet existing GMP standards. For biorefinery applications involving food-contact materials, additional safety assessments may apply under EU regulations.
OXYTRAIN assembled a strong network of 15 partners across 7 countries (Austria, Germany, Italy, Netherlands, Norway, Turkey, UK), with a notable 53% industry participation rate — well above average for academic training networks. The consortium includes 8 industrial partners and 3 SMEs alongside 7 universities, led by Rijksuniversiteit Groningen in the Netherlands. The objective explicitly names 3 industrial beneficiaries and 5 partner organisations focused on translating enzyme knowledge into real applications in textiles, pharmaceuticals, and biorefineries. This mix suggests the research was designed with commercial relevance in mind, though the primary mission remained training early-stage researchers rather than delivering market-ready products.
Rijksuniversiteit Groningen, Netherlands — reach out to the biochemistry or biotechnology department that led OXYTRAIN
Want to explore whether OXYTRAIN's enzyme technology fits your production process? SciTransfer can connect you with the right research team and provide a tailored briefing on licensing options.
